Read by QxMD icon Read

Cachexia-anorexia cancer

Alicia Stievenard, Mathieu Méquinion, Zane B Andrews, Alain Destée, Marie-Christine Chartier-Harlin, Odile Viltart, Christel C Vanbesien-Mailliot
The gastro-intestinal peptide ghrelin has been assigned many functions. These include appetite regulation, energy metabolism, glucose homeostasis, intestinal motility, anxiety, memory or neuroprotection. In the last decade, this pleiotropic peptide has been proposed as a therapeutic agent in gastroparesis for diabetes and in cachexia for cancer. Ghrelin and its receptor, which is expressed throughout the brain, play an important role in motivation and reward. Ghrelin finely modulates the mesencephalic dopaminergic signaling and is thus currently studied in pathological conditions including dopamine-related disorders...
November 30, 2016: Neuroscience and Biobehavioral Reviews
Ting Zhou, Kaixiang Yang, Sudip Thapa, Qiang Fu, Yongsheng Jiang, Shiying Yu
PURPOSE: The assessment of quality of life (QOL) is an important part of cachexia management for cancer patients. Functional assessment of anorexia-cachexia therapy (FAACT), a specific QOL instrument for cachexia patients, has not been validated in Chinese population. The aim of this study was to validate the FAACT scale in Chinese cancer patients for its future use. METHODS: Eligible cancer patients were included in our study. Patients' demographic and clinical characteristics were collected from the electronic medical records...
November 29, 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Tamás Nagykálnai, László Landherr
About 50% of all patients with cancer eventually develop anorexia/cachexia syndrome, which represents a complex clinical syndrome occurring in several illnesses, including cancer. The syndrome is characterized by systemic inflammation and primarily loss of body fat and body mass. In this review we shortly summarize the pathomechanism of anorexia/cachexia syndrome and list the current pharmacological approaches.
November 29, 2016: Magyar Onkologia
A I Graul, M Stringer, L Sorbera
Cachexia is a multiorgan, multifactorial and often irreversible wasting syndrome associated with cancer and other serious, chronic illnesses including AIDS, chronic heart failure, chronic kidney disease and chronic obstructive pulmonary disease. Treatment of the patient with cachexia is currently targeted to correcting the two underlying features of the condition: anorexia and metabolic disturbances. Greater understanding of the mechanisms behind cachexia and muscle wasting have led to new therapeutic possibilities, however...
September 2016: Drugs of Today
Diane G Portman, Sarah Thirlwell, Kristine A Donovan, Christine Alvero, Jhanelle E Gray, Rosa Holloway, Lee Ellington
This article discusses the care of a 62-year-old man with non-small-cell lung cancer and associated cancer anorexia-cachexia syndrome (CACS), and demonstrates common challenges faced by such patients and their family caregivers. The case description illustrates the fragmented approach of various disciplines to the patient's CACS care, resulting in undertreatment, delayed and burdensome visits, and patient and caregiver frustration and emotional distress. The mounting problems that arise for the patient over time exemplify the absence of a shared mental model among the various providers, patient, and caregiver for the care of CACS...
November 2016: Journal of Oncology Practice
Greetje Vanhoutte, Mick van de Wiel, Kristin Wouters, Michaël Sels, Linda Bartolomeeussen, Sven De Keersmaecker, Caroline Verschueren, Veronique De Vroey, Annemieke De Wilde, Elke Smits, Kin Jip Cheung, Liesbeth De Clerck, Petra Aerts, Didier Baert, Caroline Vandoninck, Sofie Kindt, Sofie Schelfhaut, Marc Vankerkhoven, Annelies Troch, Lore Ceulemans, Hanne Vandenbergh, Sven Leys, Tim Rondou, Elke Dewitte, Kristel Maes, Patrick Pauwels, Benedicte De Winter, Luc Van Gaal, Dirk Ysebaert, Marc Peeters
OBJECTIVE: This study aimed to provide evidence-based results on differences in overall survival (OS) rate to guide the diagnosis of cancer cachexia. DESIGN: Data collection and clinical assessment was performed every 3 months (5 visits): baseline data, muscle strength, nutritional and psychosocial status. 2 definitions on cachexia using different diagnostic criteria were applied for the same patient population. Fearon et al's definition is based on weight loss, body mass index (BMI) and sarcopenia...
2016: BMJ Open Gastroenterology
Erkan Topkan
Weight loss (WL), as a key step of the irreversible and fatal cancer-related anorexia cachexia syndrome is present to some degree in 80% of non-small cell lung cancer (NSCLC) patients upon diagnosis which has been clearly proved to negatively alter patients' performance status, quality of life (QOL), response to treatment, and prognosis. However, WL is not a problem encountered only upon diagnosis but is also commonly reported during the course of aggressive chemotherapy, radiotherapy (RT) and particularly the concurrent chemoradiotherapy (C-CRT) which may further diminish QOL measures and clinical outcomes...
October 2016: Annals of Translational Medicine
Roberto Serpe, Laura Demurtas, Marco Puzzoni, Clelia Madeddu, Mario Scartozzi
The cancer anorexia-cachexia syndrome (CACS) is considered a multifactorial syndrome that leads a general decline of the cancer patient conditions, prognosis and survival, and characterized by progressive loss of body mass and functional impairment, due to marked energy metabolism imbalance and immunological disorders. It is the cause of death in almost one out of five advanced cancer patients. CACS is also accompanied with loss of quality of life, reduced response and tolerance to anticancer therapies and affected outcome...
October 2016: Recenti Progressi in Medicina
Cong Ming-Hua, Zou Bao-Hua, Yu Lei
Anorexia cancer cachexia syndrome is prevalent in advanced cancer patients, which is featured by anorexia, decreased dietary intake, body weight loss (skeletal muscle mass loss), and unable to be reversed by routine nutritional support therapy. Up to now, the main mechanisms involved in cancer cachexia include excessive systemic inflammation, which is represented by increased plasma levels of IL-1, IL-6, TNF-alpha, tumor-induced factors, such as PIF and LMF. These factors eventually act on orexigenic and anorexigenic neurons located in hypothalamus or protein and lipid metabolism of peripheral tissues, which lead to anorexia, decreased dietary intake, enhanced basic metabolism rate and hyper catabolism...
October 18, 2016: Current Pharmaceutical Biotechnology
Willian das Neves, Christiano Robles Rodrigues Alves, Ney Robson de Almeida, Fátima Lúcia Rodrigues Guimarães, Paulo Rizzo Ramires, Patricia Chakur Brum, Antonio Herbert Lancha
AIMS: Resistance exercise training (RET) has been adopted as non-pharmacological anti-catabolic strategy. However, the role of RET to counteract cancer cachexia is still speculative. This study aimed to verify whether short-term RET would counteract skeletal muscle wasting in a severe cancer cachexia rat model. MAIN METHODS: Wistar rats were randomly allocated into four experimental groups; 1) untrained control rats (control), 2) rats submitted to RET (control+RET), 3) untrained rats injected with Walker 256 tumor cells in the bone marrow (tumor) and 4) rats injected with Walker 256 tumor cells in the bone marrow and submitted to RET (tumor+RET)...
October 15, 2016: Life Sciences
Marie François, Kuniko Takagi, Romain Legrand, Nicolas Lucas, Stephanie Beutheu, Christine Bôle-Feysot, Aurore Cravezic, Naouel Tennoune, Jean-Claude do Rego, Moïse Coëffier, Akio Inui, Pierre Déchelotte, Sergueï O Fetissov
BACKGROUND AND AIMS: Cancer chemotherapy is commonly accompanied by mucositis, anorexia, weight loss, and anxiety independently from cancer-induced anorexia-cachexia, further aggravating clinical outcome. Ghrelin is a peptide hormone produced in gastric mucosa that reaches the brain to stimulate appetite. In plasma, ghrelin is protected from degradation by ghrelin-reactive immunoglobulins (Ig). To analyze possible involvement of ghrelin in the chemotherapy-induced anorexia and anxiety, gastric ghrelin expression, plasma levels of ghrelin, and ghrelin-reactive IgG were studied in rats treated with methotrexate (MTX)...
2016: Frontiers in Nutrition
Simone Gärtner, Janine Krüger, Ali A Aghdassi, Antje Steveling, Peter Simon, Markus M Lerch, Julia Mayerle
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related mortality in both genders. More than 80% of patients suffer from significant weight loss at diagnosis and over time develop severe cachexia. Early nutritional support is therefore essential. SUMMARY: This review evaluates the different nutritional therapies, such as enteral nutrition, parenteral nutrition and special nutritional supplements, on nutritional status, quality of life and survival...
May 2016: Gastrointestinal Tumors
Ju-Hyun Jeon, Chong-Kwan Cho, So-Jung Park, Hwi-Joong Kang, Kyungmin Kim, In-Chul Jung, Young-Il Kim, Suk-Hoon Lee, Hwa-Seung Yoo
Objective The aim of this study was to determine the feasibility, acceptability, and safety of using moxibustion for treating anorexia and improving quality of life in patients with metastatic cancer. Methods We conducted a randomized sham-controlled trial of moxibustion. Sixteen patients with metastatic cancer were recruited from Daejeon, South Korea. The patients were randomly placed into a true or a sham moxibustion group and received 10 true or sham moxibustion treatments administered to the abdomen (CV12, CV8, CV4) and legs (ST36) over a 2-week period...
June 22, 2016: Integrative Cancer Therapies
Meng-Chuan Chen, Wen-Lin Hsu, Pa-An Hwang, Yen-Lin Chen, Tz-Chong Chou
Cancer cachexia is characterized by anorexia, skeletal muscle atrophy, and systemic inflammation. Fucoidan extracted from brown algae exhibits anti-inflammatory and anticancer activities. However, whether fucoidan ameliorates tumour and chemotherapy-induced muscle atrophy and -related cachectic symptoms remains unknown. Compared with mice with bladder cancer treated with chemotherapy alone (TGC group), those treated with a combination of low molecular weight fucoidan (LMWF) and chemotherapy drugs such as gemcitabine and cisplatin (TGCF) showed a significant reduction of body weight loss, muscle atrophy, and intestinal injury and dysfunction...
June 13, 2016: Oncotarget
Koji Amano, Isseki Maeda, Tatsuya Morita, Yoshiro Okajima, Takashi Hama, Maho Aoyama, Yoshiyuki Kizawa, Satoru Tsuneto, Yasuo Shima, Mitsunori Miyashita
BACKGROUND: A number of advanced cancer patients are suffering from physical and psychosocial burdens because of cancer cachexia, and these burdens also greatly impact on their family members and relationships between patients and family members. It is necessary to consider the psychosocial impact of cancer cachexia on family members of advanced cancer patients. METHODS: A cross-sectional anonymous nationwide survey was conducted involving 925 bereaved family members of cancer patients who had been admitted to 133 inpatient hospices throughout Japan...
December 2016: Journal of Cachexia, Sarcopenia and Muscle
Edson Alves de Lima Junior, Alex Shimura Yamashita, Gustavo Duarte Pimentel, Luís G O De Sousa, Ronaldo Vagner T Santos, Cinara Ludvig Gonçalves, Emilio Luiz Streck, Fábio Santos de Lira, Jose Cesar Rosa Neto
BACKGROUND: Cancer is considered the second leading cause of death in the world, and for the treatment of this disease, pharmacological intervention strategies are frequently based on chemotherapy. Doxorubicin (DOX) is one of the most widely used chemotherapeutic agents in clinical practice for treating a number of solid tumours. The treatment with DOX mimics some effects of cancer cachexia, such as anorexia, asthenia, decreases in fat and skeletal muscle mass and fatigue. We observed that treatment with DOX increased the systemic insulin resistance and caused a massive increase in glucose levels in serum...
December 2016: Journal of Cachexia, Sarcopenia and Muscle
Chunhoo Cheon, Sunju Park, Yu Lee Park, Ching-Wen Huang, Youme Ko, Bo-Hyoung Jang, Yong-Cheol Shin, Seong-Gyu Ko
INTRODUCTION: Cancer-related anorexia is the loss of appetite or desire to eat in patients with cancer. Although treatments for cancer-related anorexia do exist, patients have sought complementary and alternative medicine including herbal remedies, due to safety concerns. Sipjeondaebo-tang is one among other popular herbal medicines that are beneficial to management of anorexia in Korea. The purpose of this study is to examine the feasibility for a full randomised clinical trial of Sipjeondaebo-tang for cancer-related anorexia...
2016: BMJ Open
Tito Borner, Laura Loi, Claudio Pietra, Claudio Giuliano, Thomas A Lutz, Thomas Riediger
The gastric hormone ghrelin positively affects energy balance by increasing food intake and reducing energy expenditure. Ghrelin mimetics are a possible treatment against cancer anorexia-cachexia syndrome (CACS). This study aimed to characterize the action of the nonpeptidergic ghrelin receptor agonist HM01 on neuronal function, energy homeostasis and muscle mass in healthy rats and to evaluate its possible usefulness for the treatment of CACS in a rat tumor model. Using extracellular single-unit recordings, we tested whether HM01 mimics the effects of ghrelin on neuronal activity in the arcuate nucleus (Arc)...
July 1, 2016: American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
Joanne K Taylor, Neil Pendleton
BACKGROUND: Cachexia describes a complex pathological syndrome of muscle wasting, anorexia and weight loss. Progesterone therapies have been shown to improve appetite and promote weight gain in patients with cachexia; however, research has focused heavily on patients with cancer, and its effectiveness in other diseases remains unclear. AIMS: This systematic review aimed to present the evidence available for progesterone therapy as a treatment for non-cancer cachexia...
September 2016: BMJ Supportive & Palliative Care
Koichi Takayama, Shinji Atagi, Fumio Imamura, Hiroshi Tanaka, Koichi Minato, Toshiyuki Harada, Nobuyuki Katakami, Takuma Yokoyama, Kozo Yoshimori, Yuichi Takiguchi, Osamu Hataji, Yuichiro Takeda, Keisuke Aoe, Young Hak Kim, Soichiro Yokota, Hiroshi Tabeta, Keisuke Tomii, Yasuo Ohashi, Kenji Eguchi, Koshiro Watanabe
PURPOSE: Although cancer cachexia is mainly characterized by persistent loss of body weight (BW), usually in response to a malignancy, the pathophysiology of cachexia remains unresolved. To elucidate the relationship between the loss of BW and other related clinical factors, we conducted a nationwide, multi-institutional, prospective, observational study in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Treatment-naïve stage IV NSCLC patients with an Eastern Cooperative Oncology Group performance status (PS) of 0-2 were eligible...
August 2016: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"